Hims & Hers Health Business Summary

Hims & Hers Health, Inc. (HIMS) operates a multi-specialty direct-to-consumer (DTC) telehealth platform that generates revenue primarily through a subscription-based model for personalized prescription and over-the-counter treatments. The company’s core business is diversified across four primary segments—sexual health, hair loss, dermatology, and mental health—while aggressively expanding into high-growth vectors such as menopause care, testosterone replacement therapy, and whole-body lab testing. Despite recent regulatory headwinds and legal challenges in early 2026 regarding its compounded GLP-1 weight loss offerings, the company maintains a resilient core with approximately 70% of revenue derived from non-weight loss categories. Hims & Hers competes directly with Ro (Roman), Keeps, and Thirty Madison in the DTC wellness space, while positioning itself as a more integrated, technology-driven platform compared to broad telehealth providers like Teladoc Health. The company was founded in 2017 by Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector through the venture studio Atomic Labs. The leadership team is led by CEO Andrew Dudum and features a high-pedigree executive suite including CFO Yemi Okupe (formerly of Uber and Google), COO Mike Chi (formerly of Zola), and CTO Mo Elshenawy, who joined in 2025 from Cruise and Amazon to lead the firm’s AI-driven healthcare initiatives. In July 2025, the company further strengthened its product leadership by appointing Dheerja Kaur, formerly of Robinhood, as Chief Product Officer. The Board of Directors includes notable figures such as former FDA Deputy Commissioner Deb Autor and Lead Independent Director David Wells, with significant institutional backing from major shareholders including BlackRock and The Vanguard Group.